Known targets — ChEMBL curated mechanism
MTORPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5
The experimentally established mechanism targets of Dactolisib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR known ✓ | P42345 | 17/20 | 0.83 |
| ▸ | PIK3CA known ✓ | P42336 | 14/20 | 0.83 |
| ▸ | PIK3CD known ✓ | O00329 | 8/20 | 0.83 |
| ▸ | PIK3CG known ✓ | P48736 | 6/20 | 0.83 |
| ▸ | PIK3CB known ✓ | P42338 | 5/20 | 0.83 |
| ▸ | PIK3R1 known ✓ | P27986 | 1/20 | 0.83 |
| ▸ | PIK3R5 known ✓ | Q8WYR1 | 1/20 | 0.83 |
| ▸ | PRKDC | P78527 | 3/20 | 0.83 |
| ▸ | ATM | Q13315 | 3/20 | 0.83 |
| ▸ | PIK3C2A | O00443 | 2/20 | 0.83 |
| ▸ | PIK3C2B | O00750 | 2/20 | 0.83 |
| ▸ | ATR | Q13535 | 2/20 | 0.83 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.83 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.83 |
| ▸ | CSF1R | P07333 | 1/20 | 0.83 |
| ▸ | MET | P08581 | 1/20 | 0.83 |
| ▸ | LTK | P29376 | 1/20 | 0.83 |
| ▸ | CDK7 | P50613 | 1/20 | 0.83 |
| ▸ | NEK2 | P51955 | 1/20 | 0.83 |
| ▸ | JAK3 | P52333 | 1/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dactolisib SCHEMBL995465 | 1.00 | MTOR (0.83) | MTORPIK3CAPIK3CDPIK3CGPIK3CB | |
| SCHEMBL994756 | 0.94 | MTOR (0.73) | MTORPIK3CAPIK3CDPIK3CGPIK3CB | |
| SCHEMBL994760 | 0.93 | MTOR (0.70) | MTORPIK3CAPIK3CDPIK3CGPIK3CB | |
| SCHEMBL995934 | 0.91 | MTOR (0.68) | MTORPIK3CAPIK3CDPIK3CGPIK3CB | |
| Dactolisib SCHEMBL143623 | 0.91 | MTOR (1.00) | MTORPIK3CAPIK3CDPIK3CGPIK3CB | |
| Dactolisib SCHEMBL2424463 | 0.91 | MTOR (1.00) | MTORPIK3CAPIK3CDPIK3CGPIK3CB | |
| Dactolisib SCHEMBL29370906 | 0.91 | MTOR (1.00) | MTORPIK3CAPIK3CDPIK3CGPIK3CB | |
| Dactolisib SCHEMBL30186162 | 0.91 | MTOR (1.00) | MTORPIK3CAPIK3CDPIK3CGPIK3CB | |
| SCHEMBL994357 | 0.91 | MTOR (0.68) | MTORPIK3CAPIK3CDPIK3CGPIK3CB | |
| SCHEMBL994361 | 0.89 | PIK3CA (0.70) | MTORPIK3CAPIK3CDPIK3CGPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120202190-A | Isoquinoline derivatives as protein degrading agents, E7 degrading agents, antiviral agents, tumor therapeutic agents and immunosuppressants | RDP制药股份公司 | 2025-06-24 | — | — | CN | claimed |
| EP-4548977-A2 | NOVEL ISOQUINOLINES AS PROTEIN DEGRADERS, E7 DEGRADERS, ANTIVIRALS, TUMOR THERAPEUTICS AND IMMUNE SUPPRESSIVES | RDP Pharma AG (CH) | 2025-05-07 | — | — | EP | claimed |
| EP-4605376-A1 | ISOQUINOLINE DERIVATIVES AS PROTEIN DEGRADERS, E7 DEGRADERS, ANTIVIRALS, TUMOR THERAPEUTICS AND IMMUNE SUPPRESSIVES | RDP Pharma AG (CH) | 2025-08-27 | — | — | EP | disclosed |
| EP-4548977-A2 | NOVEL ISOQUINOLINES AS PROTEIN DEGRADERS, E7 DEGRADERS, ANTIVIRALS, TUMOR THERAPEUTICS AND IMMUNE SUPPRESSIVES | RDP Pharma AG (CH) | 2025-05-07 | — | — | EP | disclosed |
| CN-119367367-A | Application of BEZ235 in preparation of medicines for treating or improving retinal microvasculopathy | 暨南大学 | 2025-01-28 | — | — | CN | disclosed |
| US-20240208925-A1 | ISOQUINOLINE DERIVATIVES FOR USE AS ANTIVIRAL AND ANTITUMOUR AGENTS | PAGS CO., LTD. (KR) | 2024-06-27 | — | — | US | disclosed |
| WO-2024083802-A1 | ISOQUINOLINE DERIVATIVES AS PROTEIN DEGRADERS, E7 DEGRADERS, ANTIVIRALS, TUMOR THERAPEUTICS AND IMMUNE SUPPRESSIVES | VALDOSPAN GMBH (AT) | 2024-04-25 | — | — | WO | disclosed |
| CN-113559267-B | Cell death inducing agent, cell proliferation inhibiting agent, and pharmaceutical composition for treating diseases caused by abnormal cell proliferation | 日东电工株式会社 | 2024-01-12 | — | — | CN | disclosed |
| CN-113577290-B | Cell death inducing agent, cell proliferation inhibiting agent, and pharmaceutical composition for treating diseases caused by abnormal cell proliferation | 日东电工株式会社 | 2023-10-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240208925-A1 | ISOQUINOLINE DERIVATIVES FOR USE AS ANTIVIRAL AND ANTITUMOUR AGENTS | TP53, EIF2AK2, VHL | MTOR 2300/4885PIK3CA 3311/4885PIK3CD 3459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.